Patients with multiple sclerosis (MS) are treated with drugs that may impact immune responses to SARS-CoV-2 vaccination. Evaluation of “prime-boost” (heterologous) vaccination regimens including a first administration of a viral vector-based vaccine and a second one of an mRNA-based vaccine in such patients has not yet been completed. Here, we present the anti-spike protein S humoral response, including the neutralizing antibody response, in a 54-year-old MS patient who had been treated with teriflunomide for the past 2 years and who received a heterologous ChAdOx1 nCoV-19/ BNT162b2 vaccination regimen. The results showed a very strong anti-S IgG response and a good neutralizing antibody response. These results show that teriflunomide did not prevent the development of a satisfactory humoral response in this MS patient after vaccination with a ChAdOx1 nCoV-19/ BNT162b2 prime-boost protocol.
【저자키워드】 SARS-CoV-2, BNT162b2 vaccine, Antibody Response, ChAdOx1 nCoV-19 vaccine, Teriflunomide, 【초록키워드】 Vaccine, immune response, vaccination, protocol, multiple sclerosis, drug, BNT162b2, Patient, ChAdOx1, protein S, Neutralizing antibody response, Heterologous, SARS-CoV-2 vaccination, Anti-spike, anti-S IgG, administration, humoral, regimen, mRNA-based vaccine, Prevent, treated, viral vector-based, 【제목키워드】 response, ChAdOx1 nCoV-19, mRNA BNT162b2, induced, Multiple, sclerosis,